CBRNE - Vesicants, Mustard - Hd, Hn1-3, H Differential Diagnoses
- Author: Daniel J Dire, MD, FACEP, FAAP, FAAEM; Chief Editor: Robert G Darling, MD, FACEP more...
Differential Diagnoses
- Bronchitis
- Burns, Chemical
- Burns, Ocular
- Burns, Thermal
- CBRNE - Arsenicals, Arsine
- CBRNE - Chemical Decontamination
- CBRNE - Chemical Detection Equipment
- CBRNE - Chemical Warfare Agents
- CBRNE - Chemical Warfare Mass Casualty Management
- CBRNE - Evaluation of a Chemical Warfare Victim
- CBRNE - Incendiary Agents, Magnesium and Thermite
- CBRNE - Incendiary Agents, Napalm
- CBRNE - Incendiary Agents, White Phosphorus
- CBRNE - Irritants: Cs, Cn, Cnc, Ca, Cr, Cnb, PS
- CBRNE - Lung-Damaging Agents, Chlorine
- CBRNE - Lung-Damaging Agents, Phosgene
- CBRNE - Lung-Damaging Agents, Toxic Smokes: Nox, Hc, Rp, Fs, Fm, Sgf2, Teflon
- CBRNE - Personal Protective Equipment
- CBRNE - Urticants, Phosgene Oxime
- CBRNE - Vesicants, Organic Arsenicals: L, ED, MD, PD, HL
- Conjunctivitis
- Hazmat
- Pharyngitis
- Pneumonia, Bacterial
- Sinusitis
- Toxicity, Arsenic
- Toxicity, Phosgene
Sidell FR, Takafuji ET, Franz DR. Medical Aspects of Chemical and Biological Warfare. Washington, DC: Borden Institute; 1997:197-222.
Geraci MJ. Mustard gas: imminent danger or eminent threat?. Ann Pharmacother. Feb 2008;42(2):237-46. [Medline].
Wattana M, Bey T. Mustard gas or sulfur mustard: an old chemical agent as a new terrorist threat. Prehosp Disaster Med. Jan-Feb 2009;24(1):19-29; discussion 30-1. [Medline].
Lagali N, Fagerholm P. Delayed mustard gas keratitis: clinical course and in vivo confocal microscopy findings. Cornea. May 2009;28(4):458-62. [Medline].
Eisenkraft A, Krivoy A, Vidan A, Robenshtok E, Hourvitz A, Dushnitsky T. Phase I study of a topical skin protectant against chemical warfare agents. Mil Med. Jan 2009;174(1):47-52. [Medline].
Doi M, Hattori N, Yokoyama A, Onari Y, Kanehara M, Masuda K, et al. Effect of mustard gas exposure on incidence of lung cancer: a longitudinal study. Am J Epidemiol. Mar 15 2011;173(6):659-66. [Medline].
Headquarters, Department of the Army. Field Manual 8-285, Treatment of Chemical Agent Casualties and Conventional Military Chemical Injuries. Washington, DC: Dec 22 1995.
Iyriboz Y. A recent exposure to mustard gas in the United States: clinical findings of a cohort (n = 247) 6 years after exposure. MedGenMed. 2004;6(4):4. [Medline]. [Full Text].
McManus J, Huebner K. Vesicants. Crit Care Clin. Oct 2005;21(4):707-18, vi. [Medline].
Morad Y, Banin E, Averbukh E, Berenshtein E, Obolensky A, Chevion M. Treatment of ocular tissues exposed to nitrogen mustard: beneficial effect of zinc desferrioxamine combined with steroids. Invest Ophthalmol Vis Sci. May 2005;46(5):1640-6. [Medline].
Pons P, Dart RC. Chemical incidents in the emergency department: if and when. Ann Emerg Med. Aug 1999;34(2):223-5. [Medline].
Richter MN, Wachtlin J, Bechrakis NE, Hoffmann F. Keratoplasty after mustard gas injury: clinical outcome and histology. Cornea. May 2006;25(4):467-9. [Medline].
Saladi RN, Smith E, Persaud AN. Mustard: a potential agent of chemical warfare and terrorism. Clin Exp Dermatol. Jan 2006;31(1):1-5. [Medline].
Smith KJ, Hurst CG, Moeller RB, et al. Sulfur mustard: its continuing threat as a chemical warfare agent, the cutaneous lesions induced, progress in understanding its mechanism of action, its long-term health effects, and new developments for protection and therapy. J Am Acad Dermatol. May 1995;32(5 Pt 1):765-76. [Medline].
US Army Medical Research Institute of Chemical Defense. Medical Management of Chemical Casualties Handbook. 3rd ed. Aug 1999.

